Top

International Urology and Nephrology

Published in:

13-04-2023 | Dapagliflozin | Nephrology - Original Paper

The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis

Authors: Congyuan Ma, Xuanwei Li, Wenlai Li, Yue Li, Fangfang Shui, Ping Zhu

Published in: International Urology and Nephrology | Issue 12/2023

Abstract

Purpose

In recent years, increasing evidence has shown that sodium-glucose cotransporter 2 inhibitors (SGLT2i) drugs have potential renoprotective effects in patients with diabetes mellitus (DM). However, the renal protective effect of SGLT2i in non-diabetic nephropathy patients has not been extensively demonstrated. In this systematic review and meta-analysis, we aimed to evaluate the renal protective effect and safety of SGLT2i in non-diabetic nephropathy patients.

Methods

we searched for relevant clinically randomised controlled trials and analyzed the effects of SGLT2i on estimated glomerular filtration rate (eGFR), urinary albumin/creatinine ratio (UACR), and systolic blood pressure (SBP) and the incidence of adverse events in patients with non-diabetic nephropathy.

Results

We collated and analysed clinical data from six groups of patients with nondiabetic nephropathy. It was found that the SGLT2i significantly delayed the decline in eGFR [MD = 1.35 ml/min/1.73 m², 95% CI 0.84, 1.86), P < 0.0001]. Furthermore, the SGLT2i significantly reduced UACR [MD = − 24.47% l, 95% CI (− 38.9, −10.04), P = 0.0009], and showed a greater decrease in SBP [MD = − 4.13 mmHg, 95% CI (− 7.49, − 0.77), P = 0.02]. There was no significant difference in the incidence of adverse reactions between dapagliflozin/empagliflozin and the control group [OR = 1.14, 95% CI (0.88, 1.47), P = 0.33].

Conclusion

This study shows that SGLT2i help to delay the progression of non-diabetic kidney disease. Therefore, SGLT2i may contribute to the general treatment of nondiabetic nephropathy.

Available only for authorised users

Ferrannini E (2017) Sodium-glucose co-transporters and their inhibition: clinical physiology. Cell Metab 26(1):27–38. https://doi.org/10.1016/j.cmet.2017.04.011CrossRefPubMed

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334. https://doi.org/10.1056/NEJMoa1515920CrossRefPubMed

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295–2306. https://doi.org/10.1056/NEJMoa1811744CrossRefPubMed

Cooper ME, Inzucchi SE, Zinman B, Hantel S, von Eynatten M, Wanner C, Koitka-Weber A (2019) Glucose control and the effect of empagliflozin on kidney outcomes in type 2 diabetes: an analysis from the EMPA-REG OUTCOME trial. Am J Kidney Dis 74(5):713–715. https://doi.org/10.1053/j.ajkd.2019.03.432CrossRefPubMed

Tamura K, Wakui H, Azushima K, Uneda K, Umemura S (2016) Circadian blood pressure rhythm as a possible key target of SGLT2 inhibitors used for the treatment of Type 2 diabetes. Hypert res 39(6):396–398. https://doi.org/10.1038/hr.2016.1CrossRef

Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI (2018) Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int 94(1):26–39. https://doi.org/10.1016/j.kint.2017.12.027CrossRefPubMed

Vlasschaert C, Sidhu B, Silver SA (2021) Sodium/glucose cotransporter 2 inhibitors in chronic kidney disease and heart failure: ready for prime time in patients without diabetes. Curr Opin Nephrol Hypertens 30(3):361–368. https://doi.org/10.1097/mnh.0000000000000703CrossRefPubMed

Teo YH, Teo YN, Syn NL, Kow CS, Yoong CSY, Tan BYQ, Yeo TC, Lee CH, Lin W, Sia CH (2021) Effects of sodium/glucose Cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Amer Heart Assoc. 10(5):019463. https://doi.org/10.1161/jaha.120.019463CrossRef

Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL (2020) Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 8(7):582–593. https://doi.org/10.1016/s2213-8587(20)30162-5CrossRefPubMed

10.

Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC (2020) Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol dial transplant 35(2):274–282. https://doi.org/10.1093/ndt/gfz290CrossRefPubMedPubMedCentral

11.

Antlanger M, Domenig O, Kaltenecker CC, Kovarik JJ, Rathkolb V, Müller MM, Schwaiger E, Hecking M, Poglitsch M, Säemann MD, Kopecky C (2022) Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double-blind, placebo-controlled exploratory trial. Diabetes Obes Metab 24(5):816–826. https://doi.org/10.1111/dom.14639CrossRefPubMedPubMedCentral

12.

Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(2):117–127. https://doi.org/10.1056/NEJMoa2204233CrossRefPubMed

13.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Revista espanola de cardiologia (English ed) 74(9):790–799. https://doi.org/10.1016/j.rec.2021.07.010CrossRefPubMed

14.

Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215–224. https://doi.org/10.1016/j.kint.2021.03.033CrossRefPubMed

15.

Heerspink HJL, Jongs N, Chertow GM, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefansson BV, Toto RD, Wheeler DC, Greene T (2021) Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9(11):743–754. https://doi.org/10.1016/s2213-8587(21)00242-4CrossRefPubMed

16.

Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF, Langkilde AM, McMurray JJV, Rossing P, Nowicki M, Wittmann I, Correa-Rotter R, Sjöström CD, Toto RD, Heerspink HJL (2022) Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol dialy transplant 37(9):1647–1656. https://doi.org/10.1093/ndt/gfab335CrossRef

17.

Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial (2022). Nephrology, dialysis, transplantation 37 (7):1317–1329. Doi: https://doi.org/10.1093/ndt/gfac040

18.

McGuire DK, Shih WJ, Cosentino F, Charbonnel B, Cherney DZI, Dagogo-Jack S, Pratley R, Greenberg M, Wang S, Huyck S, Gantz I, Terra SG, Masiukiewicz U, Cannon CP (2021) Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. JAMA cardiology 6(2):148–158. https://doi.org/10.1001/jamacardio.2020.4511CrossRefPubMed

19.

Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B (2020) Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Amer Heart Assoc 9(3):014908. https://doi.org/10.1161/jaha.119.014908CrossRef

20.

Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 393(10166):31–39. https://doi.org/10.1016/s0140-6736(18)32590-xCrossRefPubMed

21.

Li LF, Ding LL, Zhan ZL, Qiu M (2021) Meta-analysis on the safety and cardiorenal efficacy of SGLT2 inhibitors in patients without T2DM. Front cardiovasc med. 8:690529. https://doi.org/10.3389/fcvm.2021.690529CrossRefPubMedPubMedCentral

22.

Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):422–434. https://doi.org/10.1016/j.jacc.2019.11.031CrossRefPubMed

23.

Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S (2020) ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3–5: A network meta-analysis of randomised clinical trials. Drugs 80(8):797–811. https://doi.org/10.1007/s40265-020-01290-3CrossRefPubMedPubMedCentral

24.

Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, Cushman WC, Hawfield AT, Johnson KC, Lewis CE, Oparil S, Rocco MV, Sink KM, Whelton PK, Wright JT Jr, Basile J, Beddhu S, Bhatt U, Chang TI, Chertow GM, Chonchol M, Freedman BI, Haley W, Ix JH, Katz LA, Killeen AA, Papademetriou V, Ricardo AC, Servilla K, Wall B, Wolfgram D, Yee J (2017) Effects of intensive BP control in CKD. J Am Soc Nephrol 28(9):2812–2823. https://doi.org/10.1681/asn.2017020148CrossRefPubMedPubMedCentral

25.

De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R (2020) Nephroprotection by SGLT2 inhibition: back to the future? J clin med. https://doi.org/10.3390/jcm9072243CrossRefPubMedPubMedCentral

Title: The efficacy and safety of SGLT2 inhibitors in patients with non-diabetic chronic kidney disease: a systematic review and meta-analysis
Authors: Congyuan Ma
Xuanwei Li
Wenlai Li
Yue Li
Fangfang Shui
Ping Zhu
Publication date: 13-04-2023
Publisher: Springer Netherlands
Keywords: Dapagliflozin
Empagliflozin
Diabetic Nephropathy
Diabetes
Chronic Kidney Disease
Type 2 Diabetes
Published in: International Urology and Nephrology / Issue 12/2023
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-023-03586-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2023

Effect of stress hyperglycaemia on acute kidney injury in non-diabetic critically ill patients?

Application of image overlapping in percutaneous nephrolithotomy

Global trends and hotspots in IgA nephropathy: a bibliometric analysis and knowledge map visualization from 2012 to 2023

Parasympathetic activity and total fibrotic kidney in autosomal-dominant polycystic kidney disease patients: a pilot study

Improving sleep quality is essential for enhancing soluble Klotho levels in hemodialysis patients

Are SGLT-2 inhibitors “the elephant in the room” of non-diabetic glomerulonephritis? Considerations about the background immunosuppressive treatment

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials